BJMO - volume 13, issue 8, december 2019
D. De Maeseneer MD, E. Werbrouck MD, S. De Keukeleire MSc, S. Rottey MD, PhD
In recent years, innovations in renal, bladder and prostate cancer treatments have been introduced at a rapid pace. Every year, oncological societies had to update treatment guidelines according to new insights and results of large phase III trials. This article focuses on practice changing data from the 2019 ESMO congress in Barcelona, Spain.
Read moreBJMO - volume 13, issue 6, october 2019
T. Vermassen PhD, T. Roumeguère MD, Y. Neybuch MD, L. Hoekx MD, I. Fele , B. Sautois MD, PhD, W. Everaerts MD, PhD, D. De Maeseneer MD, F. Lecouvet MD, PhD, N. Lumen MD, PhD, P. Ost MD, PhD, S. Rorive MD, PhD, S. Stroobants MD, PhD, P. Dirix MD, PhD, S. Rottey MD, PhD
Castrate-resistant prostate cancer (CRPC) is characterised by complex strategies for therapy and follow-up. In order to standardise CRPC cancer care on a national basis, an integrated care pathway was devised, based on clinical governance principles and acknowledged best practice, in order to reduce length of hospital stay, reduce costs of patient care, improve patient outcomes (e.g. Quality-of-Life, complications), etc. Therefore, a steering group of Belgian experts, consisting of medical oncologist, urologists, radiation oncologists, oncology nurses, pathologists and nuclear medicines, was assembled to discuss the need for an integrated care pathway for CRPC in Belgium. This was made possible through the financial support of Astellas Belgium. An extensive integrated care pathway was discussed with various stages, depending on the disease status of the patient. Belgian implementation could lead towards further standardisation of cancer care for CRPC patients although several important matters still have to be discussed or adapted. Further assessment and inter-hospital deliberation seems required to ensure a national implementation of the CRPC integrated care pathway.
(BELG J MED ONCOL 2019;13(6): 219–226)
Read moreBJMO - volume 12, issue 5, september 2018
D. De Maeseneer MD, K. Decaestecker PhD, S. Rottey MD, PhD
Treatment for urothelial cancer has undergone rapid change. Cisplatin based chemotherapy should be given in the neo-adjuvant setting in muscle invasive bladder cancer and could play a role in trimodality therapy when combined with surgery and radiotherapy. Genetic profiling has differentiated several subtypes of urothelial cancer, mimicking progress seen in breast cancer. Of these subtypes, p53 like tumours are less likely to respond to neo-adjuvant chemotherapy. In metastatic urothelial cancer, systemic immunotherapy (checkpoint inhibitors) has shown promising results in first line and second line patients. In a phase III trial, pembrolizumab, an anti-PD1 (programmed cell death 1) antibody, showed a survival benefit in second line metastatic urothelial cancer and should be the new standard of care. In patients who are cisplatin ineligible checkpoint can be used in first line, but no phase III data are available.
(BELG J MED ONCOL 2018;12(5):212–217)
Read moreBJMO - 12, issue 3, february 2018
B. De Laere , M. Mayrhofer , T. Whitington , P-J. Van Dam , P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, W. Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , N. Beije , I. De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , L. Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , J. Del-Favero , S. Sleijfer , A. Uhlen , J. Yachnin , S. Van Laere PhD, H. Grönberg , J. Lindberg , L. Dirix MD, PhD
BJMO - 2017, issue 3, february 2017
B. De Laere , P. Van Oyen , C. Ghysel , P. Ost MD, PhD, W. Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD, PhD
BJMO - volume 7, issue 4, september 2013
C. Van Praet MD, D. De Maeseneer MD, N. Lumen MD, PhD, S. Rottey MD, PhD
Since the 1940’s the androgen receptor has been the main target for systemic therapy in prostate cancer. Classic hormonal therapy aims at lowering serum testosterone levels or block the androgen receptor ligand-binding domain. Despite disease progression, castration-resistant prostate cancer remains predominantly androgen-driven as novel secondary hormonal therapy with abiraterone acetate or enzalutamide has demonstrated increased overall survival. Promising androgen synthesis inhibitors (orteronel, galeterone), androgen receptor inhibitors (ARN-509, EPI-001, AZD3514) and heat-shock protein modulators are under investigation. Given the upcoming arsenal of systemic therapies and the molecular heterogeneity of castration-resistant prostate cancer, patient-tailored therapy strategies are being explored.
(BELG J MED ONCOL 2013;7(3):111–8)
Read more
Top
